1. Home
  2. DMO vs LUNG Comparison

DMO vs LUNG Comparison

Compare DMO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Mortgage Opportunity Fund Inc.

DMO

Western Asset Mortgage Opportunity Fund Inc.

HOLD

Current Price

$9.77

Market Cap

116.9M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.99

Market Cap

97.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMO
LUNG
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.9M
97.1M
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
DMO
LUNG
Price
$9.77
$1.99
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
45.6K
321.2K
Earning Date
01-01-0001
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$9.73
$1.13
52 Week High
$12.08
$2.89

Technical Indicators

Market Signals
Indicator
DMO
LUNG
Relative Strength Index (RSI) 22.69 47.86
Support Level N/A $1.20
Resistance Level $11.20 $2.16
Average True Range (ATR) 0.11 0.13
MACD -0.02 -0.03
Stochastic Oscillator 7.05 32.26

Price Performance

Historical Comparison
DMO
LUNG

About DMO Western Asset Mortgage Opportunity Fund Inc.

Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: